DCM
LXEO icon

DAFNA Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

DAFNA Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Hold
377,059
– – 0.33% 49
2026
Q1 		$2.16M Buy
377,059
+36,200
+11% +$257K 0.49% 45
2025
Q4 		$3.38M Sell
340,859
-17,224
-5% -$157K 0.79% 34
2025
Q3 		$2.38M Sell
358,083
-20,000
-5% -$96.7K 0.59% 39
2025
Q2 		$1.52M Hold
378,083
– – 0.42% 45
2025
Q1 		$1.31M Sell
378,083
-15,000
-4% -$66.5K 0.37% 48
2024
Q4 		$2.59M Buy
393,083
+142,500
+57% +$1.12M 0.66% 35
2024
Q3 		$2.27M Buy
+250,583
New +$2.99M 0.54% 43

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

DAFNA Capital Management's LXEO Position: Q2 2026 in Review

DAFNA Capital Management held its Lexeo Therapeutics (LXEO) position steady in Q2 2026 at 377,059 shares worth $1.76M. The position accounts for 0.33% of the portfolio, ranked #49.

DAFNA Capital Management first reported a position in LXEO in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.38M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • DAFNA Capital Management held 377,059 shares of Lexeo Therapeutics worth $1.76M as of Q2 2026.
  • DAFNA Capital Management left its Lexeo Therapeutics share count unchanged in Q2 2026.
  • Lexeo Therapeutics made up 0.33% of DAFNA Capital Management's portfolio in Q2 2026, its #49 holding.
  • DAFNA Capital Management first reported a position in Lexeo Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • DAFNA Capital Management's Lexeo Therapeutics position peaked at $3.38M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.